Law360, New York (March 08, 2011, 5:12 PM ET) -- The U.S. Food and Drug Administration issued new warnings last month for Abbott Laboratories' Kaletra after serious health problems were reported in premature babies receiving the oral anti-HIV drug.
A new warning on the Kaletra label approved by the FDA on Feb. 24 says premature babies should not be given Kaletra until 14 days after their original due date — not their actual date of birth — and that infants younger than 14 days of age should only receive the drug if a doctor believes the...
FDA Warns Of Risks To Babies From HIV Drug Kaletra
To view the full article, take a free trial now.
